DelveInsight’s, “Refractory Metastatic Melanoma Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Refractory Metastatic Melanoma Research. Learn more about our innovative pipeline today! @ Refractory Metastatic Melanoma Pipeline Outlook

Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report

• In July 2025, Genmab announced clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo.
• DelveInsight’s Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Refractory Metastatic Melanoma treatment.
• The leading Refractory Metastatic Melanoma Companies such as BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.
• Promising Refractory Metastatic Melanoma Pipeline Therapies such as GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others.

Stay informed about the cutting-edge advancements in Refractory Metastatic Melanoma treatments. Download for updates and be a part of the revolution in Dermatology care @ Refractory Metastatic Melanoma Clinical Trials Assessment

Refractory Metastatic Melanoma Emerging Drugs Profile

• BNT111: BioNTech SE

BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory/relapsed, unresectable Stage III or IV melanoma. BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as uridine mRNA-lipoplex formulation. Over 90% of patients with cutaneous melanomas express at least one of these antigens. The BNT111 program has also received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration. Currently, the drug is in Phase II stage of its development for the treatment of Refractory Metastatic Melanoma.

• GD2-SADA: Y-mAbs Therapeutics

The GD2-SADA construct is created using SADA technology, that utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs attached to the tumor target in order to radiate the tumor. This provides the possibility of targeting tumors with precision while minimizing radiation of normal tissues. The SADA technology platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for theragnostic purposes. Currently, the drug is in Phase I stage of its development for the treatment of Refractory Metastatic Melanoma.

The Refractory Metastatic Melanoma Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Metastatic Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Metastatic Melanoma Treatment.
• Refractory Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Refractory Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Metastatic Melanoma market.

Learn more about Refractory Metastatic Melanoma Drugs opportunities in our groundbreaking Refractory Metastatic Melanoma research and development projects @ Refractory Metastatic Melanoma Unmet Needs

Refractory Metastatic Melanoma Companies

BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.

Refractory Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Refractory Metastatic Melanoma treatment by visiting our website. Stay informed about how we’re transforming the future of dermatology @ Refractory Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives

Scope of the Refractory Metastatic Melanoma Pipeline Report

• Coverage- Global
• Refractory Metastatic Melanoma Companies- BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others.
• Refractory Metastatic Melanoma Pipeline Therapies- GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others.
• Refractory Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Refractory Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Refractory Metastatic Melanoma Pipeline on our website @ Refractory Metastatic Melanoma Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Refractory Metastatic Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Refractory Metastatic Melanoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Refractory Metastatic Melanoma Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BNT111: BioNTech SE
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. GD2-SADA: Y-mAbs Therapeutics
17. Drug profiles in the detailed report…
18. Pre-clinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Refractory Metastatic Melanoma Key Companies
23. Refractory Metastatic Melanoma Key Products
24. Refractory Metastatic Melanoma- Unmet Needs
25. Refractory Metastatic Melanoma- Market Drivers and Barriers
26. Refractory Metastatic Melanoma- Future Perspectives and Conclusion
27. Refractory Metastatic Melanoma Analyst Views
28. Refractory Metastatic Melanoma Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-metastatic-melanoma-pipeline-insight